Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Fosun Pharma Acquires China Rights to Stroke Drug in $32.5 Million Agreement

publication date: Sep 27, 2018

Jinzhou Ahon Pharma, a subsidiary of Shanghai Fosun Pharma, in-licensed greater China rights to a candidate for an ischemic stroke treatment from DiaMedica Therapeutics of Minneapolis in a $32.5 million agreement. DM199 (synthetic KLK1 protein) can be administered up to 24 hours after the onset of a stroke, longer than the 3 to 4.5 hours of tPA, the current standard of care. Previously, Fosun made an equity investment in DiaMedica. Ahon specializes in cardiovascular and CNS drugs. More details....

Stock Symbols: (HK: 02196: SHA: 600196) (TSX: DMA; OTCQB: DMCAF)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.